Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients-Reference-Cited by-同舟云学术

Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients

Published:2015-12-06 Issue:2 Volume:36 Page:189-197
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Everson Gregory T.¹,Sims Karen D.²,Thuluvath Paul J.³,Lawitz Eric⁴,Hassanein Tarek⁵,Rodriguez-Torres Maribel⁶,Desta Tadesse⁷,Hawkins Trevor⁸,Levin James M.⁹,Hinestrosa Federico¹⁰,Rustgi Vinod¹¹,Schwartz Howard¹²,Younossi Zobair¹³,Webster Lynn¹⁴,Gitlin Norman¹⁵,Eley Timothy²,Huang Shu-Pang²,McPhee Fiona¹⁶,Grasela Dennis M.²,Gardiner David F.²

Affiliation:

1. University of Colorado Denver; Aurora CO USA

2. Bristol-Myers Squibb; Princeton NJ USA

3. Mercy Medical Center; Baltimore MD USA

4. The Texas Liver Institute; University of Texas Health Science Center; San Antonio TX USA

5. Southern California GI and Liver Centers; Coronado CA USA

6. Fundación de Investigación; San Juan PR USA

7. Precision Research Institute; San Diego CA USA

8. Southwest CARE Center; Santa Fe NM USA

9. Dean Foundation for Health, Research and Education Inc; Madison WI USA

10. Orlando Immunology Center; Orlando FL USA

11. The Thomas Starzl Transplant Institute; University of Pittsburgh Medical Center; Pittsburgh PA USA

12. Miami Research Associates; South Miami FL USA

13. Inova Fairfax Hospital; Center for Liver Diseases; Falls Church VA USA

14. PRA Health Sciences; Raleigh NC USA

15. Atlanta Gastroenterology Associates' Liver Center; Atlanta GA USA

16. Bristol-Myers Squibb; Wallingford CT USA

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12964/fullpdf

Reference28 articles.

1. World Health Organization Hepatitis C key facts

2. Global burden of hepatitis C: considerations for healthcare providers in the United States;Averhoff;Clin Infect Dis,2012

3. Current management and perspectives for HCV recurrence after liver transplantation;Coilly;Liver Int,2013

4. American Association for the Study of Liver Diseases, Infectious Diseases Society of America Recommendations for testing, managing, and treating hepatitis C http://www.hcvguidelines.org/fullreport/hcv-testing-and-linkage-care

5. EASL Recommendations on Treatment of Hepatitis C 2015;European Association for the Study of the Liver;J Hepatol,2015

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses;European Journal of Pharmaceutics and Biopharmaceutics;2023-02

2. Mechanistic Studies of a Pd-Catalyzed Direct Arylation En Route to Beclabuvir: Dual Role of a Tetramethylammonium Cation and an Unusual Turnover-Limiting Step;ACS Catalysis;2021-02-10

3. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C;Expert Opinion on Pharmacotherapy;2020-01-08

4. Design and evaluation of novel tetracyclic benzofurans as palm site allosteric inhibitors of HCV NS5B polymerase;Bioorganic & Medicinal Chemistry Letters;2019-12

5. Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects;Clinical Pharmacology in Drug Development;2019-01-10